Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.
Bisoendial
Radjesh J
RJ
Hovingh
G Kees
GK
El Harchaoui
Karim
K
Levels
Johannes H M
JH
Tsimikas
Sotirios
S
Pu
Kewei
K
Zwinderman
Aeilko E
AE
Kuivenhoven
Jan Albert
JA
Kastelein
John J P
JJ
Stroes
Erik S G
ES
D000328:Adult; D000577:Amides; D002352:Carrier Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism; D053480:Cholesterol Ester Transfer Proteins; D004952:Esters; D005260:Female; D006023:Glycoproteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D013438:Sulfhydryl Compounds / Q000008:administration & dosage*; D013631:Tangier Disease / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
D000577:Amides; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D004952:Esters; D006023:Glycoproteins; D013438:Sulfhydryl Compounds; C411602:dalcetrapib; D002784:Cholesterol